What is Ado-trastuzumab emtansine?

Category: Prescription Drugs

Most popular types: Kadcyla


Ado-trastuzumab emtansine is a HER2-targeted product that uses the monoclonal antibody trastuzumab to help deliver the microtubule inhibitor emtansine. This agent is used for the treatment of patients with HER2-positive, metastatic breast cancer.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 2
None 0

Commonly reported side effects and conditions associated with Ado-trastuzumab emtansine

Side effect Patients
Fatigue 1
Nausea 1
Thrombocytopenia (low platelet count) 1
Adherence Evaluations
Always 2
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 0
Not at all hard to take 1
Cost per month
Cost per month Evaluations
$200+ 1
$100-199 0
$50-99 0
$25-49 1
< $25 0
Not specified 0

What people switch to and from

Patients started taking Ado-trastuzumab emtansine after stopping:

Treatment Patients
Pertuzumab 1
Last updated:
There are no evaluations for Ado-trastuzumab emtansine.